DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Squamous Cell Carcinoma of the Head and Neck | Disease Landscape and Forecast | G7 | 2016
Until recently, SCCHN treatment lacked promising late-phase agents; the only targeted therapy approved for the indication was Bristol-Myers Squibb/Eli Lilly/Merck KGaA’s Erbitux. However, the…
Glioblastoma, Prostate cancer, Squamous Cell Carcinoma of the Head and Neck | Access and Reimbursement | US | 2016
The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and…
Squamous Cell Carcinoma of the Head and Neck | Niche and Rare Pharmacor | G7 | 2014
Squamous cell carcinoma of the head and neck (SCCHN) is one of the six most frequently diagnosed malignancies worldwide. Second/third primary tumors are the main threats to long-term survival once…
Contemporary Topics in the Treatment of Non-Small-Cell Lung Cancer: Physicians, Payers, and Pathologists as Gatekeepers to Market Access
Based on a survey of 100 medical oncologists and 30 MCO pharmacy and medical directors, this report explores the market access challenges facing key current and emerging brands used in the…
